Free Trial
→ China’s message to Trump (From Porter & Company) (Ad)tc pixel

hVIVO (LON:HVO) Trading Down 7.9% - What's Next?

Written by MarketBeat
September 22, 2025
hVIVO logo with Medical background

Key Points

  • hVIVO plc's stock price decreased by 7.9%, closing at GBX 9.10 ($0.12), after reaching a low of GBX 9.04 ($0.12) during trading on Monday.
  • Investment analysts have given hVIVO a consensus rating of "Buy" with an average price target of GBX 28, despite the recent stock price drop.
  • The company specializes in pharmaceutical services and contract research, conducting human challenge clinical trials for various health conditions, including vaccines and antivirals.
  • Interested in hVIVO? Here are five stocks we like better.

hVIVO plc (LON:HVO - Get Free Report) dropped 7.9% during trading on Monday . The stock traded as low as GBX 9.04 ($0.12) and last traded at GBX 9.10 ($0.12). Approximately 3,571,943 shares traded hands during trading, an increase of 24% from the average daily volume of 2,891,166 shares. The stock had previously closed at GBX 9.88 ($0.13).

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on HVO. Shore Capital reaffirmed a "buy" rating and issued a GBX 35 price objective on shares of hVIVO in a research note on Tuesday, July 22nd. Peel Hunt reiterated an "add" rating and issued a GBX 21 target price on shares of hVIVO in a report on Tuesday, July 29th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, hVIVO has an average rating of "Buy" and an average target price of GBX 28.

Read Our Latest Research Report on hVIVO

hVIVO Stock Performance

The firm has a market cap of £58.66 million, a PE ratio of 550.71 and a beta of 0.97. The business has a 50-day simple moving average of GBX 10.01 and a 200 day simple moving average of GBX 12.82. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16.

hVIVO (LON:HVO - Get Free Report) last announced its earnings results on Tuesday, September 23rd. The company reported GBX (0.29) earnings per share (EPS) for the quarter. hVIVO had a net margin of 25.96% and a return on equity of 47.93%. Equities research analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.

hVIVO Company Profile

(Get Free Report)

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.

Read More

Should You Invest $1,000 in hVIVO Right Now?

Before you consider hVIVO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.

While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Ride The A.I. Megaboom Cover
7 Stocks to Ride The A.I. Megaboom


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report
Like this article? Share it with a colleague.